Ocugen grants MENA rights for OCU400 gene therapy
+1 new source since this summary was written
On October 14, 2026, Ocugen entered an exclusive licensing arrangement with Roots Pharmaceutical and Al-Dhow International Holding covering OCU400 for the Middle East and North Africa. The agreement provides Ocugen with an upfront fee and initial development payments of up to $4 million, potential sales-based milestones of up to $255 million, and royalties of 22% on net sales. Ocugen remains responsible for making and delivering the therapy, while topline results from its Phase 3 liMeliGhT trial are expected in the first quarter of 2027.
Why it matters
The deal gives Ocugen a regional commercialization partner and creates potential milestone and royalty income if OCU400 is successfully developed, approved, and adopted. Ocugen will retain the product supply role, while the key near-term clinical catalyst is the planned Phase 3 readout in the first quarter of 2027.
Key facts
- 1The license covers exclusive OCU400 rights in the Middle East and North Africa. stocktitan.net
- 2The agreement includes initial development payments of up to $4 million, sales milestones of up to $255 million, and royalties of 22% on net sales. stocktitan.net
- 3Ocugen will produce OCU400 and provide it to the regional partners. investing.com
- 4The company expects topline Phase 3 liMeliGhT data in the first quarter of 2027. investing.com
- 5Retinitis pigmentosa prevalence in the covered region is estimated at 10 to 20 times the level in the U.S. and EU. stocktitan.net
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.